Singapore, Oct. 6 -- Belgium-based UCB Pharma and US-based Tanner Pharma Group have initiated a partnership in Southeast Asia, includingcountries of Cambodia, Indonesia, Laos, Malaysia, Mongolia, Myanmar, Nepal, Philippines, Singapore, Republic of Korea, Thailand and Vietnam, to enable access to innovative treatments for patients with epilepsy.
"We are proud to work with UCB to provide a means for epilepsy patients in Southeast Asia to access innovative medicines. This partnership reflects the types of companies Tanner strives to associate with," said Rob Keel, Executive Vice President of the Managed Access Program division at Tanner Pharma.
UCB is a global biopharmaceutical company focused on the discovery and development of innovative...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.